Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings

American Journal of Health-System Pharmacy

Volumn 72, Issue 18, 2015, Pages 1544-1554

  Corrigan, Megan ^a   Wilson, Suprat Saely ^b   Hampton, Jeremy ^c,d  

^a ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c TRUMAN MEDICAL CENTER   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS USED IN EMERGENCY MEDICINE; FENTANYL; FLUMAZENIL; GLUCAGON; HALOPERIDOL; HYDROMORPHONE; KETAMINE; MIDAZOLAM; NALOXONE; NOSE DROPS; SUFENTANIL;

ANALGESIA; ANTICONVULSANT THERAPY; APNEA; ATAXIA; BITTER TASTE; CEREBROSPINAL FLUID; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DYSARTHRIA; DYSPHASIA; DYSPHORIA; EMERGENCY CARE; EMERGENCY WARD; EPILEPTIC STATE; FIRST PASS EFFECT; HUMAN; HYPOGLYCEMIA; HYPOXIA; MIGRAINE; NASAL DRUG DELIVERY SYSTEM; NAUSEA; NEBULIZATION; NOSE CAVITY; NOSE MUCOSA; PAIN; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SYSTEMIC CIRCULATION; TRANQUILIZING ACTIVITY; VISUAL DISORDER; VOMITING; WEAKNESS; EMERGENCY HEALTH SERVICE; INTRANASAL DRUG ADMINISTRATION; PATIENT SAFETY; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; EMERGENCY MEDICAL SERVICES; EMERGENCY SERVICE, HOSPITAL; HUMANS; PATIENT SAFETY; TREATMENT OUTCOME;

EID: 84971007930     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140630     Document Type: Review

References (92)

1. Hochreiter MC, Barton LL. Epidemiology of needlestick injury in emergency medical service personnel. J Emerg Med. 1988; 6:9-12.
2. Nisbet AC. Intramuscular gluteal injections in the increasingly obese population: retrospective study. BMJ. 2006; 332:637-8.
3. Bhalla MC, Gable BD, Frey JA et al. Predictors of epinephrine autoinjector needle length inadequacy. Am J Emerg Med. 2013; 31:1671-6.
4. Anatomy and physiology of the nose. In: Chien YW, Su KE, Chang SF, eds. Nasal systemic drug delivery. New York: Marcel Dekker; 1989:1-26.
5. Hussain AA. Mechanism of nasal absorption of drugs. Prog Clin Biol Res. 1989; 292:261-72.
6. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002; 46:759-70.
7. McMartin C, Hurchinson LF, Hyde R et al. Analysis of structure requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci. 1987; 76:535-40.
8. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci. 2004; 26:137-42.
9. Dale O. Intranasal administration of opioids/fentanyl-physiological and pharmacological aspects. Eur J Pain Suppl. 2010; 43:187-90.
10. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 1998; 5:415-41.
11. Sakane T, Akizuki M, Yoshida M et al. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol. 1991; 436:449-51.
12. Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin after intranasal administration. J Pharmacol Exp Ther. 2004; 309:469-75.
13. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003; 43:149-73.
14. Minn A, Leclerc S, Heydel JM et al. Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrier. J Drug Target. 2002; 10:285-96.
15. Corbo DC, Liu JC, Chien YW. Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharm Res. 1989; 6:848-52.
16. Huang CH, Kimura R, Bawarshi-Nassar R et al. Mechanism of nasal absorption of drugs II: absorption of L-tyrosine and the effect of structural modification on its absorption. J Pharm Sci. 1985; 74:1298-301.
17. Matsuyama T, Morita T, Horikiri Y et al. Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant. J Control Release. 2006; 110:347-52.
18. Jiang XG, Lu X, Cui JB et al. [Studies on octanol-water partition coefficient and nasal drug absorption.] Yao Xue Xue Bao. 1997; 32:458-60. In Chinese.
19. Misra A, Kher G. Drug delivery systems from nose to brain. Curr Pharm Biotechnol. 2012; 13:2355-79.
20. Teleflex. LMA MAD Nasal: needle-free intranasal drug delivery. www.lmana.com/pwpcontrol.php?pwpID=6359 (accessed 2014 Nov 25).
21. McCormick AS, Thomas VL, Berry D, Thomas PW. Plasma concentrations and sedation scores after nebulized and intranasal midazolam in healthy volunteers. Br J Anaesth. 2008; 100:631-6.
22. Bommer R. Latest advances in drugdelivery technology. Med Device Technol. 1999; 10:22-8.
23. Merkus P, Ebbens FA, Muller B et al. Influence of anatomy and head position on intranasal drug deposition. Eur Arch Otorhinolaryngol. 2006; 263:827-32.
24. BD. Accuspray nasal spray system. www.bd.com/pharmaceuticals/products/nasalspray. asp (accessed 2014 Nov 25).
25. Go Medical. Nasal PCA. www.gomedical.com.au/products/nasalspray.php (accessed 2014 Nov 25).
26. Kurvetech. ViaNase data sheet. www.kurvetech.com/pdf/ViaNaseDataSheet.pdf (accessed 2014 Apr 8).
27. Hardy JG, Lee SW, Wilson CG. Intranasal drug delivery by spray and drops. J Pharm Pharmacol. 1985; 37:294-7.
28. Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. Br J Clin Pharmacol. 2001; 51:103-5.
29. Henry RJ, Ruano N, Casto D, Wolf RH. A pharmacokinetic study of midazolam in dogs: nasal drop vs. atomizer administration. Pediatr Dent. 1998; 20:321-6.
30. Striebel HW, Krämer J, Luhmann I et al. [Pharmacokinetics of intranasal fentanyl.] Schmerz. 1993; 7:122-5. In German.
31. Grape S, Schug SA, Lauer S et al. Formulations of fentanyl for the management of pain. Drugs. 2010; 70:57-72.
32. Paech MJ, Lim CB, Banks SL et al. A new formulation of nasal fentanyl spray for postoperative analgesia: a pilot study. Anaesthesia. 2003; 58:740-4.
33. Younge P, Nicol M, Kendall J et al. A prospective randomized pilot comparison of intranasal fentanyl and intramuscular morphine for analgesia in children presenting to the emergency department with clinical fractures. Emerg Med. 1999; 11:90-4.
34. Borland M, Jacobs I, King B et al. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med. 2007; 49:335-40.
35. Saunders M, Adelgais K, Nelson D. Use of intranasal fentanyl for the relief of pediatric orthopedic trauma pain. Acad Emerg Med. 2010; 17:1155-61.
36. Cole J, Shepherd M, Young P. Intranasal fentanyl in 1-3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia. Emerg Med Australas. 2009; 21:395-400.
37. Finn M, Harris D. Intranasal fentanyl for analgesia in the paediatric emergency department. Emerg Med J. 2010; 27:300-1.
38. Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. Emerg Med. 2002; 14:275-80.
39. Borland M, Milsom S, Esson A. Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial. Emerg Med Australas. 2011; 23:202-8.
40. Crellin D, Xiu Ling R, Babl FE. Does the standard intravenous solution of fentanyl (50 mcg/mL) administered intranasally have analgesic efficacy? Emerg Med Australas. 2010; 22:62-7.
41. Holdgate A, Cao A, Lo KM. The implementation of intranasal fentanyl for children in a mixed adult and pediatric emergency department reduces time to analgesic administration. Acad Emerg Med. 2010; 17:214-7.
42. Karlsen AP, Pedersen DM, Trautner S et al. Safety of intranasal fentanyl in the out-of-hospital setting: a prospective observational study. Ann Emerg Med. 2014; 63:699-703.
43. Rickard C, O'Meara P, McGrail M et al. A randomized controlled trial of intranasal fentanyl vs intravenous morphine for analgesia in the prehospital setting. Am J Emerg Med. 2007; 25:911-7.
44. Middleton PM, Simpson PM, Sinclair G et al. Effectiveness of morphine, fentanyl, and methoxyflurane in the prehospital setting. Prehosp Emerg Care. 2010; 14:439-47.
45. Helmers JH, Noorduin H, Van Peer A et al. Comparison of intravenous and intranasal sufentanil absorption and sedation. Can J Anaesth. 1989; 36:494-7.
46. Steenblik, J, Goodman M, Davis V et al. Intranasal sufentanil for the treatment of acute pain in a winter resort clinic. Am J Emerg Med. 2012; 30:1817-21.
47. Stephen R, Lingenfelter E, Broadwater-Hollifield C, Madsen T. Intranasal sufentanil provides adequate analgesia for emergency department patients with extremity injuries. J Opioid Manag. 2012; 8:237-41.
48. Lim SC, Paech MJ, Goy R et al. Pharmacokinetics and bioavailability of hydromorphone nasal spray. J Pharm Pract Res. 2008; 38:191-5.
49. Coda BA, Rudy AC, Archer SM et al. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 2003; 97:117-23.
50. Wermeling DP, Clinch T, Rudy AC et al. A multicenter, open-label, exploratory dose-ranging trial of intranasal hydromorphone for managing acute pain from traumatic injury. J Pain. 2010; 11:24-31.
51. Green SM, Roback MG, Kennedy RM et al. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med. 2011; 57:449-60.
52. White PF, Dworsky WA, Horai Y, Trevor AJ. Comparison of continuous infusion fentanyl or ketamine versus thiopental-determining the mean effective serum concentrations for outpatient surgery. Anesthesiology. 1983; 59:564-9.
53. Malinovsky JM, Servin F, Cozian A et al. Ketamine and norketamine plasma concentrations after IV, nasal and rectal administration in children. Br J Anaesth. 1996; 77:203-7.
54. Andolfatto G, Willman E, Joo D et al. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013; 20:1050-4.
55. Johansson J, Sjöberg J, Nordgren M et al. Prehospital analgesia using nasal administration of S-ketamine-a case series. Scand J Trauma Resusc Emerg Med. 2013; 21:38.
56. Yeaman F, Meek R, Egerton-Warburton D et al. Sub-dissociative-dose intranasal ketamine for moderate to severe pain in adult emergency department patients. Emerg Med Australas. 2014; 26:237-42.
57. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology. 1999; 53:537-42.
58. Leao AA. Spreading depression of activity in cerebral cortex. J Neurophysiol. 1944; 7:359-90.
59. Rashidy-Pour A, Motaghed-Larijani Z, Bures J. Tolerance to ketamine-induced blockade of cortical spreading depression transfers to MK-801 but not to AP5 in rats. Brain Res. 1995; 693:64-9.
60. Afridi SK, Giffin NJ, Kaube H et al. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013; 80:642-7.
61. Kotwal RS, Butler FK, Montgomery HR et al. The tactical combat casualty card (TCCCC) guidelines-proposed change 1301. J Spec Oper Med. 2013; 13:82-7.
62. Black IH, McManus J. Pain management in current combat operations. Prehosp Emerg Care. 2009; 13:223-7.
63. Carr DB, Goudas LC, Denman WT et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. 2004; 108:17-27.
64. Huge V, Lauchart M, Magerl W et al. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain. 2010; 14:387-94.
65. Wermeling DP. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics. 2009; 6:352-8.
66. Knowester PD, Jonker DM, Van Der Hoeven RT et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002; 53:501-7.
67. Scheepers M, Scheepers B, Clarke M et al. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? Seizure. 2000; 9:417-22.
68. Fisgin T, Gurer Y, Tezic T et al. Efects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol. 2002; 17:123-6.
69. Holsti M, Sill BL, Firth SD et al. Prehospital intranasal midazolam for the treatment of pediatric seizures. Pediatr Emerg Care. 2007; 23:148-53.
70. Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol. 2006; 34:355-9.
71. De Haan GJ, van der Geest P, Doelman G et al. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia. 2010; 51:478-82.
72. Lahat E, Goldman M, Barr J et al. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ. 2000; 321:83-6.
73. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004; 5:253-5.
74. Mauri MC, Volonteri LS, Colasanti A et al. Clinical pharmacokinetics of atypical antipsychotics. Clin Pharmacokinet. 2007; 46:359-88.
75. Miller JL, Ashford JW, Archer SM et al. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. Pharmacotherapy. 2008; 28:875-82.
76. Van Putten T, Marder SR, Mintz J et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry. 1992; 149:500-5.
77. Robertson TM, Hendey GW, Stroh G et al. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009; 13:512-5.
78. Barton ED, Ramos J, Colwell CB et al. Intranasal administration of naloxone by paramedics. Prehosp Emerg Care. 2002; 6:54-8.
79. Barton ED, Colwell CB, Wolfe T et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005; 29:265-71.
80. Kelly AM, Kerr D, Dietze P et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005; 182:24-7.
81. Scheepers LD, Montgomery CJ, Kinahan AM et al. Plasma concentrations of flumazenil following intranasal administration in children. Can J Anesth. 2000; 47:120-4.
82. Heard C, Creighton P, Lerman J. Intranasal flumazenil and naloxone to reverse over-sedation in a child undergoing dental restorations. Pediatr Anesth. 2009; 19:795-9.
83. Kreshak AA, Cantrell FL, Clark RF et al. A poison center's ten-year experience with flumazenil administration to acutely poisoned adults. J Emerg Med. 2012; 43:677-82.
84. Mordel A, Winkler E, Almog S et al. Seizures after flumazenil administration in a case of combined benzodiazepine and tricyclic antidepressant overdose. Crit Care Med. 1992; 20:1733-4.
85. Rosenfalck AM, Bendtson I, Jorgensen S, Binder C. Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin-dependent) diabetic patients. Diabetes Res Clin Pract. 1992; 17:43-50.
86. Merkus F, Schipper N, Hermens W et al. Absorption enhancers in nasal drug delivery: efficacy and safety. J Control Release. 1993; 24:201-8.
87. Pontiroli AE, Alberetto M, Pozza G. Intranasal glucagon raises blood glucose concentrations in healthy volunteers. Br Med J. 1983; 287:462-3.
88. Stenninger E, Aman J. Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1993; 36:931-5.
89. Slama G, Alamowitch C, Desplanque N et al. A new non-invasive method for treating insulin-reaction: intranasal lypophylized glucagon. Diabetologia. 1990; 33:671-4.
90. Pontiroli AE, Calderara A, Pajetta E et al. Intranasal glucagon as a remedy for hypoglycemia. Diabetes Care. 1989; 12:604-8.
91. Hvidberg A, Djurup R, Hilsted J. Glucose recovery after intranasal glucagon during hypoglycaemia in man. Eur J Clin Pharmacol. 1994; 46:15-7.
92. Sibley T, Jacobsen R, Salomone J. Successful administration of intranasal glucagon in the out-of-hospital environment. Prehosp Emerg Care. 2013; 17:98-102.